Norway's public health institute recommends axing AstraZeneca jab
It comes a day after Denmark became the first country in Europe to abandon the jab over links with very rare blood clots.
Norway should stop using AstraZeneca's COVID vaccine, says the country's public health institute.
It comes a day after Denmark became the first country in Europe to abandon the jab over links with very rare blood clots.
Both the World Health Organization and the European Medicines Agency have said the benefits of the vaccine outweigh its risks.
"There is now significantly more knowledge about the connection between the AstraZeneca vaccine and the rare and serious incidents of low platelets, blood clots and bleeding than when Norway chose to put further use of the AstraZeneca vaccine on pause in March," said Geir Bukholm, director of infection control at Norway's National Institute of Public Health.
"Based on this knowledge, we have arrived at a recommendation that the AstraZeneca vaccine be removed from the coronary vaccination programme in Norway."
On March 11, authorities had suspended the rollout of the vaccine after a small number of people who had received the jab were hospitalised with a combination of blood clots and a low count of platelets, with three cases proving fatal.
Bukholm said that now, with "significantly more knowledge" about the connection between the AstraZeneca vaccine and rare incidents of blood clotting and low platelets, Norway should cease use of the vaccine.
The institute estimated that pulling distribution of the AstraZeneca jab would likely bring about a delay in overall vaccine rollout by two weeks.
Bukholm said that it had not been easy to come to that recommendation. However, he suggested he believe it was a necessary step.
Those who have already received the first dose of the AstraZeneca vaccine are expected to be offered another coronavirus jab as their second dose.
However, the country's public health institute said it would be offering more information on the specifics of the programme in the coming days.
It comes a day after Denmark became the first country in Europe to abandon the jab over links with very rare blood clots.
Both the World Health Organization and the European Medicines Agency have said the benefits of the vaccine outweigh its risks.
"There is now significantly more knowledge about the connection between the AstraZeneca vaccine and the rare and serious incidents of low platelets, blood clots and bleeding than when Norway chose to put further use of the AstraZeneca vaccine on pause in March," said Geir Bukholm, director of infection control at Norway's National Institute of Public Health.
"Based on this knowledge, we have arrived at a recommendation that the AstraZeneca vaccine be removed from the coronary vaccination programme in Norway."
On March 11, authorities had suspended the rollout of the vaccine after a small number of people who had received the jab were hospitalised with a combination of blood clots and a low count of platelets, with three cases proving fatal.
Bukholm said that now, with "significantly more knowledge" about the connection between the AstraZeneca vaccine and rare incidents of blood clotting and low platelets, Norway should cease use of the vaccine.
The institute estimated that pulling distribution of the AstraZeneca jab would likely bring about a delay in overall vaccine rollout by two weeks.
Bukholm said that it had not been easy to come to that recommendation. However, he suggested he believe it was a necessary step.
Those who have already received the first dose of the AstraZeneca vaccine are expected to be offered another coronavirus jab as their second dose.
However, the country's public health institute said it would be offering more information on the specifics of the programme in the coming days.
AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
